Anthony Yazbeck: Why the Hemolysin Test Matters More Than You Think
Anthony Yazbeck, Application Specialist at Atom Medical-Dora, shared a post on LinkedIn:
”Why the Hemolysin Test Matters More Than You Think
In transfusion medicine, compatibility goes beyond ABO typing — and this is where the hemolysin test becomes critical.
Hemolysins are antibodies capable of destroying red blood cells, particularly anti-A and anti-B, which play a major role in non-identical (non-iso) group transfusions.
Why does this matter?
In group O donors, plasma may contain anti-A and anti-B antibodies. When transfused into A, B, or AB recipients, these antibodies can attack the recipient’s red blood cells, leading to hemolytic transfusion reactions.
While antibody titration is often used to assess risk, it only measures the quantity of antibodies — not their ability to cause damage.
The real clinical concern lies in hemolysins: antibodies that can actively activate complement and destroy red blood cells.
This is why hemolysin testing is essential:
- Detects clinically significant anti-A and anti-B hemolysins
- Adds functional insight beyond antibody titers
- Reduces risk in non-iso group transfusions
- Strengthens donor selection and blood safety
In resource-limited settings, overlooking this step can increase transfusion risks. Strengthening awareness and implementation of hemolysin screening can make a life-saving difference.
Safe blood isn’t just about how much antibody is present — but what it can do.”
Stay updated withHemostasis Today.
-
Nov 9, 2026, 13:48PF4-ELISA–Negative HIT: Are We Missing a New Class of Anti-PF4 Immunothrombotic Disease?
-
Nov 9, 2026, 13:07Nandini Sadasivam: Gene Therapy for Sickle Cell Disease and Thalassaemia
-
Nov 9, 2026, 13:04Raising Awareness of Bleeding Disorders in Women and Girls – EHC
-
Nov 9, 2026, 12:59Rahul Bohra: Exploring the Complex Mechanisms of Sickle Cell Disease
-
Nov 9, 2026, 12:53Three Years of Movement and Thrombosis Awareness in the Czech Republic – World Thrombosis day
-
Nov 9, 2026, 12:51Octavio Marques Pontes-Neto: Intensive Blood-Pressure Control Reduces Cardiovascular Events After Ischemic Stroke
-
Nov 9, 2026, 12:49Irma Bagdoniene: What Really Makes Us Live Longer
-
Nov 9, 2026, 12:47Imo Akpan: Announcing the 2027 Women’s Hematology Summit
-
Nov 9, 2026, 12:45Shadi Yaghi: Rethinking Antithrombotic Therapy After Stroke